Mirum Pharmaceuticals (MIRM) Enterprise Value (2019 - 2026)

Mirum Pharmaceuticals' Enterprise Value history runs 9 years deep, the most recent figure standing at -$386.3 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 39.11% year-over-year to -$386.3 million; the TTM figure through Mar 2026 stood at -$386.3 million (down 39.11% YoY), while the FY2025 annual figure was -$383.3 million, down 36.54% from the prior year.
• Enterprise Value for Q1 2026 stood at -$386.3 million, down from -$383.3 million in the prior quarter.
• The five-year high for Enterprise Value was -$94.0 million in Q3 2025, with the low at -$434.9 million in Q3 2022.
• The 5-year median for Enterprise Value is -$286.3 million (2023), against an average of -$280.5 million.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 129.3% in 2024, then surged 66.95% in 2025.
• Mirum Pharmaceuticals' Enterprise Value stood at -$251.7 million in 2022, then fell by 13.75% to -$286.3 million in 2023, then grew by 1.95% to -$280.7 million in 2024, then tumbled by 36.54% to -$383.3 million in 2025, then decreased by 0.76% to -$386.3 million in 2026.
• Business Quant data shows MIRM's Enterprise Value at -$386.3 million in Q1 2026, -$383.3 million in Q4 2025, and -$94.0 million in Q3 2025.